AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02162563
Drug: FOLFOXIRI with bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
Trial: NCT02162563
Drug: FOLFOX/ FOLFIRI with panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
Trial: NCT01410695
Drug: masitinib 3 mg
RxNorm normalized name: Axitinib
DrugBank: Masitinib (DB11526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01410695
Drug: masitinib 6.0 mg
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01327638
Drug: Other COX-2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with SpA/AS who took other COX-2 inhibitors
Trial: NCT04839237
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
Trial: NCT04839237
Drug: Liraglutide;metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
Trial: NCT00310830
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
Trial: NCT00304954
Drug: Intravenous Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
Trial: NCT00304954
Drug: Intravenous Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
Trial: NCT01669044
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
Trial: NCT01669044
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
Trial: NCT00123331
Drug: Cyclosporine discontinuation
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04262869
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04262869
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04262869
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02626182
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active sildenafil
Trial: NCT03578276
Drug: Pred-Gati-Brom
RxNorm normalized name: GATIFLOXACIN HEMIHYDRATE 5 mg in 1 mL / BROMFENAC 0.75 mg in 1 mL / PREDNISOLONE ACETATE 10 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS [Pred-Gati-Brom]
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
Trial: NCT03578276
Drug: Gatifloxacin Ophthalmic
RxNorm normalized name: gatifloxacin ophthalmic
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT00923494
Drug: 20 ml of ropivacaine 0.5%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Trial: NCT00923494
Drug: 30 ml of ropivacaine 0.5%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Trial: NCT00003301
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00400790
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol used as the primary anaesthetic agent
Trial: NCT00400790
Drug: desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane used as the primary anaesthetic
Trial: NCT00923494
Drug: 40 ml of ropivacaine 0.5%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Trial: NCT01406873
Drug: Mexiletine
RxNorm normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
Trial: NCT00781131
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin 75 or 150 mg
Trial: NCT01902173
Drug: Dabrafenib Mesylate
RxNorm normalized name: dabrafenib mesylate
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01902173
Drug: Trametinib Dimethyl Sulfoxide
RxNorm normalized name: Trametinib Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01902173
Drug: Uprosertib
RxNorm normalized name: Uprosertib
DrugBank: Uprosertib (DB11969)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00325429
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01907724
Drug: Simeprevir
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir will be supplied as 75 mg capsules for oral administration.
Trial: NCT00699634
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
Trial: NCT00039416
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00350519
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
Trial: NCT02197221
Drug: Bortezomib-Melphalan
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
Trial: NCT02197221
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan will be administered on day -2. The PBSC will be injected on day 0.
Trial: NCT01537549
Drug: alpha-lipoic acid and L-acetyl carnitine
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
Trial: NCT02301962
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
Trial: NCT03063489
Drug: Loteprednol Etabonate Ophthalmic Gel
RxNorm normalized name: Loteprednol Etabonate Ophthalmic Gel
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
Trial: NCT00478361
Drug: Gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.
Trial: NCT00478361
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 135 mg/m\^2 IV over 1 hour
Trial: NCT00478361
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneously injection on day 1.
Trial: NCT03066440
Drug: Lactated Ringers
RxNorm normalized name: lactated ringers
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Trial: NCT01990898
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
Trial: NCT02883049
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT03433326
Drug: Elbasvir/Grazoprevir
RxNorm normalized name: ELBASVIR/GRAZOPREVIR
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
Trial: NCT01861119
Drug: Silicone gel Kelo-cort™;
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01861119
Drug: Onion extract gel Contractubex™
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01440595
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grazoprevir 100 mg tablets once daily for 12 weeks.
Trial: NCT02883049
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, or SC
Trial: NCT02883049
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02883049
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02883049
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO or IV
Trial: NCT01440595
Drug: Peginterferon alfa-2b (Peg-IFN)
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Trial: NCT01440595
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Trial: NCT03292965
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
Trial: NCT03292965
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
Trial: NCT00853931
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
Trial: NCT04602390
Drug: ANK-700
RxNorm normalized name: aNK cells
DrugBank: Activated natural killer cell therapy (DB17172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT02883049
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02883049
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02883049
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or IV
Trial: NCT02883049
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02883049
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04221542
Drug: AMG 509
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
Trial: NCT04221542
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone administered as oral tablets.
Trial: NCT04221542
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide administered as oral tablets.
Trial: NCT04191499
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
Trial: NCT04191499
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
Trial: NCT04191499
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
Trial: NCT03379675
Drug: JNJ-53718678 500 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
Trial: NCT03379675
Drug: JNJ-53718678 80 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Trial: NCT02008656
Drug: Oxaliplatin (OXAL)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03416374
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules
Trial: NCT03416374
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib injections
Trial: NCT02008656
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03416374
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib intravenous infusions
Trial: NCT03416374
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules
Trial: NCT03416374
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets
Trial: NCT04488107
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years.
Trial: NCT01295931
Drug: Indocyanine Green (IC-Green)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
Trial: NCT02262728
Drug: Simeprevir
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
Trial: NCT02262728
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir 60 mg tablet orally once daily for 12 weeks
Trial: NCT02262728
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir 400 mg tablet orally once daily for 12 weeks
Trial: NCT04625270
Drug: avutometinib (VS-6766)
RxNorm normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: avutometinib (VS-6766) monotherapy
Trial: NCT04625270
Drug: avutometinib (VS-6766) and defactinib
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: avutometinib (VS-6766) and defactinib combination
Trial: NCT03257215
Drug: Stoss vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
Trial: NCT03257215
Drug: Daily vitamin D
RxNorm normalized name: Baby Super Daily Vitamin D3-Vitamin E 400 International Units-1 International Units/0.027mL Drops
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
Trial: NCT04075266
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Trial: NCT00955227
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks